• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jose M. Teixeira, PhD


  • Tanwar PS, Kaneko-Tarui T, Lee HJ, Zhang L, Teixeira JM.PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression.Carcinogenesis. 2013 Apr;34(4):893-901.
  • Tanwar PS, Commandeur AE, Zhang L, Taketo MM, Teixeira JM.The Mullerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained β-catenin signaling.Carcinogenesis. 2012 Sep 28.
  • Tanwar PS, Kaneko-Tarui T, Zhang L, Teixeira JM.Altered LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption of Sertoli cell polarity and spermatogenesis.Hum Mol Genet. 2012 Oct 15;21(20):4394-405.
  • Tanwar PS, Kaneko-Tarui T, Zhang L, Tanaka Y, Crum CP, Teixeira JM.Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.PLoS Genet. 2012 Aug;8(8):e1002906.
  • Tanwar PS, Zhang L, Roberts DJ, Teixeira JM.Stromal Deletion of the APC Tumor Suppressor in Mice Triggers Development of Endometrial Cancer.Cancer Res. 2011 Mar 1;71(5):1584-96.
  • Park JH, Daheron L, Kantarci S, Lee BS, Teixeira JM.Human endometrial cells express elevated levels of pluripotent factors and are more amenable to reprogramming into induced pluripotent stem cells.Endocrinology. 2011 Mar;152(3):1080-9.
  • Wei X, Dombkowski D, Meirelles K, Pieretti-Vanmarcke R, Szotek PP, Chang HL, Preffer FI, Mueller PR, Teixeira J, Maclaughlin DT, Donahoe PK.Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics.Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18874-9.
  • Papakostas TD, Pieretti-Vanmarcke R, Nicolaou F, Thanos A, Trichonas G, Koufomichali X, Anago K, Donahoe PK, Teixeira J, MacLaughlin DT, Vavvas D.Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.Protein Expr Purif. 2010 Mar;70(1):32-8.
  • Chang HL, Senaratne TN, Zhang L, Szotek PP, Stewart E, Dombkowski D, Preffer F, Donahoe PK, Teixeira J.Uterine leiomyomas exhibit fewer stem/progenitor cell characteristics when compared with corresponding normal myometrium.Reprod Sci. 2010 Feb;17(2):158-67.
  • Tanwar PS, Kaneko-Tarui T, Zhang L, Rani P, Taketo MM, Teixeira J.Constitutive WNT/beta-catenin signaling in murine Sertoli cells disrupts their differentiation and ability to support spermatogenesis.Biol Reprod. 2010 Feb;82(2):422-32.
  • Tanwar PS,Lee HJ,Zhang L,Zukerberg LR,Taketo MM,Rueda BR,Teixeira JM.Constitutive Activation of Beta-Catenin in Uterine Stroma and Smooth Muscle Leads to the Development of Mesenchymal Tumors in Mice.Biol Reprod. 2009 Sep;81(3):545-52.
  • Lee HJ, Teixeira J.Parthenogenesis in human oocytes that were collected from resected ovarian tissue and matured in vitro.Stem Cells Dev.;18(6):941-6.
  • Viswanathan SR,Powers JT,Einhorn W,Hoshida Y,Ng TL,Toffanin S,O'Sullivan M,Lu J,Phillips LA,Lockhart VL,Shah SP,Tanwar PS,Mermel CH,Beroukhim R,Azam M,Teixeira J,Meyerson M,Hughes TP,Llovet JM,Radich J,Mullighan CG,Golub TR,Sorensen PH,Daley GQ.Lin28 promotes transformation and is associated with advanced human malignancies.Nat Genet. 2009 Jul;41(7):843-8.
  • Berin I, Teixeira J.Utility of serum antimüllerian hormone/Müllerian-inhibiting substance for predicting ovarian reserve in older women.Menopause.;15(5):824-6.
  • Szotek PP,Chang HL,Brennand K,Fujino A,Pieretti-Vanmarcke R,Lo Celso C,Dombkowski D,Preffer F,Cohen KS,Teixeira J,Donahoe PK.Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics.Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12469-73.
  • Lee HJ, Teixeira J.Evidence of a role for androgens in embryonic stem cell function and differentiation.Endocrinology. 2008 Jan;149(1):3-4.
  • Renlund N, Pieretti-Vanmarcke R, O'Neill FH, Zhang L, Donahoe PK, Teixeira J.c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction.Endocrinology. 2008 Jan;149(1):108-15.
  • Renlund N, O'Neill FH, Zhang L, Sidis Y, Teixeira J.Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor.J Endocrinol. 2007 Oct;195(1):95-103.
  • Szotek PP, Chang HL, Zhang L, Preffer F, Dombkowski D, Donahoe PK, Teixeira J.Adult mouse myometrial label-retaining cells divide in response to gonadotropin stimulation.Stem Cells. 2007 May;25(5):1317-25.
  • Zhan Y, Fujino A, MacLaughlin DT, Manganaro TF, Szotek PP, Arango NA, Teixeira J, Donahoe PK.Mllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mllerian duct regression.Development. 2006 Jun;133(12):2359-69.
  • Arango NA, Szotek PP, Manganaro TF, Oliva E, Donahoe PK, Teixeira J.Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium.Dev Biol. 2005 Dec 1;288(1):276-83.
  • Arango NA, Pearson EJ, Donahoe PK, Teixeira J.Genomic structure and expression analysis of the mouse testis-specific ribbon protein (Trib) gene.Gene. 2004 Dec 8;343(1):221-7.
  • Trbovich AM, Martinelle N, O'Neill FH, Pearson EJ, Donahoe PK, Sluss PM, Teixeira J.Steroidogenic activities in MA-10 Leydig cells are differentially altered by cAMP and Mllerian inhibiting substance.J Steroid Biochem Mol Biol. 2004 Oct;92(3):199-208.
  • Fynn-Thompson E, Cheng H, Teixeira J.Inhibition of steroidogenesis in Leydig cells by Mllerian-inhibiting substance.Mol Cell Endocrinol. 2003 Dec 15;211(1-2):99-104.
  • Donahoe PK, Clarke T, Teixeira J, Maheswaran S, MacLaughlin DT.Enhanced purification and production of Mllerian inhibiting substance for therapeutic applications.Mol Cell Endocrinol. 2003 Dec 15;211(1-2):37-42.
  • Houk CP, Pearson EJ, Martinelle N, Donahoe PK, Teixeira J.Feedback inhibition of steroidogenic acute regulatory protein expression in vitro and in vivo by androgens.Endocrinology. 2004 Mar;145(3):1269-75.
  • Bdcarrats GY, O'Neill FH, Norwitz ER, Kaiser UB, Teixeira J.Regulation of gonadotropin gene expression by Mullerian inhibiting substance.Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9348-53.
  • Laurich VM, Trbovich AM, O'Neill FH, Houk CP, Sluss PM, Payne AH, Donahoe PK, Teixeira J.Mllerian inhibiting substance blocks the protein kinase A-induced expression of cytochrome p450 17alpha-hydroxylase/C(17-20) lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation.Endocrinology. 2002 Sep;143(9):3351-60.
  • Lorenzo HK, Teixeira J, Pahlavan N, Laurich VM, Donahoe PK, MacLaughlin DT.New approaches for high-yield purification of Mllerian inhibiting substance improve its bioactivity.J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):89-98.
  • Teixeira J, Maheswaran S, Donahoe PK.Mllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications.Endocr Rev. 2001 Oct;22(5):657-74.
  • Trbovich AM, Sluss PM, Laurich VM, O'Neill FH, MacLaughlin DT, Donahoe PK, Teixeira J.Mllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents.Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3393-7.
  • Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK.Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.Clin Cancer Res. 1999 Nov;5(11):3488-99.
  • Teixeira J, Kehas DJ, Antun R, Donahoe PK.Transcriptional regulation of the rat Mllerian inhibiting substance type II receptor in rodent Leydig cells.Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13831-8.
  • Teixeira J, Fynn-Thompson E, Payne AH, Donahoe PK.Mllerian-inhibiting substance regulates androgen synthesis at the transcriptional level.Endocrinology. 1999 Oct;140(10):4732-8.
  • Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, Maclaughlin DT, Donahoe PK.Developmental expression of a candidate mllerian inhibiting substance type II receptor.Endocrinology. 1996 Jan;137(1):160-5.